Home/Filings/4/0001225208-13-003518
4//SEC Filing

Edwards Lifesciences Corp 4

Accession 0001225208-13-003518

$EWCIK 0001099800operating

Filed

Feb 7, 7:00 PM ET

Accepted

Feb 8, 4:59 PM ET

Size

14.8 KB

Accession

0001225208-13-003518

Insider Transaction Report

Form 4
Period: 2013-02-06
KEHL JOHN H JR
CVP, Strategy & Corp Dev
Transactions
  • Sale

    Common Stock

    2013-02-06$86.58/sh300$25,974118,000 total
  • Exercise/Conversion

    Common Stock

    2013-02-06$21.95/sh+12,500$274,438115,178 total
  • Exercise/Conversion

    Common Stock

    2013-02-06$13.81/sh+3,122$43,115118,300 total
  • Sale

    Common Stock

    2013-02-06$85.84/sh15,322$1,315,240102,678 total
  • Exercise/Conversion

    Employee Stock Option (Right to Acquire)

    2013-02-063,1220 total
    Exercise: $13.81From: 2004-04-04Exp: 2013-04-03Common Stock (3,122 underlying)
  • Exercise/Conversion

    Employee Stock Option (Right to Acquire)

    2013-02-0612,50037,500 total
    Exercise: $21.95From: 2007-05-11Exp: 2013-05-10Common Stock (12,500 underlying)
Footnotes (5)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 28, 2012.
  • [F2]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.
  • [F3]This transaction was executed in multiple trades at prices ranging from $86.56 to $86.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $85.45 to $86.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.

Documents

1 file

Issuer

Edwards Lifesciences Corp

CIK 0001099800

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001099800

Filing Metadata

Form type
4
Filed
Feb 7, 7:00 PM ET
Accepted
Feb 8, 4:59 PM ET
Size
14.8 KB